COMPARISON OF DEXMEDETOMIDINE AND REMIFENTANIL FOR POSTOPERATIVE PAIN IN TRANSPHENOIDAL Pituitary SURGERY

Study Overview
=================
Brief Summary
-----------------
In patients with pituitary adenoma scheduled for endoscopic transsphenoidal pituitary surgery, it was aimed to compare the efficacy of postoperative pain relief of a selective α-2 agonist Dexmedetomidine and the rapid and short-acting opioid Remifentanil using the Numerical Rating Scale (NRS) administered alongside propofol in perioperative maintenance anesthesia. .

Official Title
-----------------
COMPARISON OF DEXMEDETOMIDINE AND REMIFENTANIL FOR POSTOPERATIVE PAIN IN TRANSPHENOIDAL Pituitary SURGERY

Conditions
-----------------
Postoperative Pain

Intervention / Treatment
-----------------
* Drug: Dexmedetomidine
* Drug: Remifentanyl


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-65 years old ASA-1 and ASA-2 patients Exclusion Criteria: Patients in need of postoperative intensive care

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| GROUP USING REMIFENTANYL<br>THE GROUP USING PEROPERATIVE REMIFENTANYL AND PROPOFOL IN TRANSSPHENOIDAL Pituitary Surgery 0.01-0.2 μg /kg /min Remifentanyl and 3-12 mg/kg/h propofol | Drug: Remifentanyl<br>* Efficacy of remifentanyl on postoperative pain in patients undergoing transsphenoidal pituitary surgery<br>|
| GROUP USING DEXMEDETOMIDINE<br>THE GROUP USING PEROPERATIVE DEXMEDETOMIDINE AND PROPOFOL IN TRANSSPHENOIDAL Pituitary Surgery 0.01-0.02 μg/kg/min ( 0.5 μg/kg/h) continuous infusion of dexmedetomidine 1 mcg/kg 10 minutes after a loading dose and 3-12 mg/kg/h propofol | Drug: Dexmedetomidine<br>* Efficacy of dexmedetomidine on postoperative pain in patients undergoing transsphenoidal pituitary surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative pain scale | Comparison of postoperative Numerical Rating Scale(NRS) values of both study arms(min 0, max 10; 10 is unbearable pain ) | at post anesthesia care unit (T1) | 
| postoperative pain scale | Comparison of postoperative Numerical Rating Scale(NRS) values of both study arms(min 0, max 10; 10 is unbearable pain ) | 2 hours after surgery (T2) | 
| postoperative pain scale | Comparison of postoperative Numerical Rating Scale(NRS) values of both study arms(min 0, max 10; 10 is unbearable pain ) | 8 hours after surgery (T3) | 
| postoperative pain scale | Comparison of postoperative Numerical Rating Scale(NRS) values of both study arms(min 0, max 10; 10 is unbearable pain ) | 24 hours after surgery (T4) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| need for analgesics | Comparison of whether there is a need for additional POSTOPERATIVE analgesic medication | Additional analgesic drug requirements at post anesthesia care unit (T1) | 
| need for analgesics | Comparison of whether there is a need for additional POSTOPERATIVE analgesic medication | Additional analgesic drug requirements at 2 hours after surgery (T2) | 
| need for analgesics | Comparison of whether there is a need for additional POSTOPERATIVE analgesic medication | Additional analgesic drug requirements at 8 hours after surgery (T3) | 
| need for analgesics | Comparison of whether there is a need for additional POSTOPERATIVE analgesic medication | Additional analgesic drug requirements at 24 hours after surgery (T4) | 
| Comparison of postoperative nausea-vomiting rate | Comparison of postoperative nausea-vomiting rate | at post anesthesia care unit (T1) | 
| Comparison of postoperative nausea-vomiting rate | Comparison of postoperative nausea-vomiting rate | 2 hours after surgery (T2) | 
| Comparison of postoperative nausea-vomiting rate | Comparison of postoperative nausea-vomiting rate | 8 hours after surgery (T3) | 
| Comparison of postoperative nausea-vomiting rate | Comparison of postoperative nausea-vomiting rate | 24 hours after surgery (T4) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
DEXMEDETOMİDİNE, REMİFENTANYL, pituitary SURGERY